Geron (GERN) In Stem Cell Deal With GE Healthcare
More News related to GE
- Notable Analyst Rating Changes 11/06: GE, CBS, HD/LOW, M Upgrade; ESLR, RMD, SUN Downgrade
- Dually Upgrade on GE (GE) Working, Stock Up 5%
- Bernstein Upgraded General Electric (GE) to Outperform
- Oppenheimer Gets Bullish on GE (GE), Upgrades to Outperform
- Oppenheimer Upgrades GE to Outperform, $18 Price Target
More News related to GERN
- Notable Analyst Rating Changes 11/02: MOT, UFS, GNW, EL, JWN, WY, RCL, CS Upgraded; RIMM, PALM, CMCSA, ERJ, GERN Downgraded
- Needham & Co Downgrades Geron Corporation (GERN) to Hold
- Needham Downgrades Geron (GERN) to Hold
- Merriman Curhan Ford Reiterates 'Buy' Geron Corporation (GERN); Important Stem Cell Visibility
- Geron (GERN) Announces Plan to Advance Clinical Development of Stem Cell Product; Will Enable Reinitiation of Phase I Trial
GE Healthcare, a unit of General Electric Company (NYSE: GE), and Geron Corporation (Nasdaq: GERN) entered into a global exclusive license and alliance agreement to develop and commercialize cellular assay products derived from human embryonic stem cells (hESCs) for use in drug discovery, development and toxicity screening.
The program will use stem cells derived from hESC lines listed on the NIH Human Pluripotent Stem Cell Registry.
Financial terms are not being disclosed.
Related Categories
FDAMomentum Movers
Stocks Mentioned
+0.90Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
